One approach towards efficient drug targeting efforts for COVID-19 is to repurpose medicines developed for other diseases. Here, Professor Christopher Basler outlines a recent study, published in Cell Reports, where scientists from the Institute for Biomedical Sciences at Georgia State University, US, in collaboration with industry partners, developed assays to…
List view / Grid view
In this article, Professor Forest White, Department of Biological Engineering at MIT, and Dr Lauren Stopfer, Scientist at BioNTech, present a novel assay approach for the rapid, reproducible and accurate identification of potential therapeutic targets using mass spectrometry.
Don’t miss the latest product hub from Fluidic Analytics, detailing the Fluidity One-W Serum which enables comprehensive profiling of protein-protein interactions, such as the antibody response to SARS-CoV-2, based on affinity – a crucial characteristic of protein interactions that traditional tests cannot easily quantify.
Exploring the intra-protein non-covalent interactions in the S1 domain of the SARS-CoV-2 S1 Spike protein
The Spike (S) protein is a promising drug target in the quest to develop vaccines and antivirals for SARS-CoV-2 to treat and prevent COVID-19. Intra-protein interaction energy landscape mapping efforts have recently identified key interactions that may be crucial for the S protein’s ability to bind to receptor proteins on…
The National Institute of Health envisions a plan for managing tuberculosis in the 21st century. Included in this proposal is targeting host proteins as an add-on therapy to antibiotics. Infectious disease biologists are focusing on this strategy and it is a topic of active research. Recently, a multinational research team…
In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against the virus.
In this application note, Fluidic Analytics show that by using MDS on the Fluidity One-W Serum we can accurately detect and characterise the binding affinity of antibodies to virus proteins directly in human serum.
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
Adeno-associated virus (AAV)-mediated gene therapies allow for the treatment of a growing number of diseases; however, the presence of neutralising antibodies can lead to limitations of this technology, particularly for patients who may be excluded due to these pre-existing or developing neutralising antibodies. Recently, a study was published in Nature…
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
29 May 2020 | By Fluidic Analytics
Styrene–maleic acid (SMA) copolymers have become popular tools used in membraneprotein research as they can extract both lipids and membrane proteins from cellular membranes while preserving the bilayer structure of the membrane in so-called nanodiscs.
31 July 2019 | By Fluidic Analytics
Join us as we discuss the latest data from the literature and application studies where diffusional sizing (MDS) is used to assess a variety of protein interactions – even of difficult targets.